Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Prescient Therapeutics Limited ( (AU:PTX) ) has issued an update.
Prescient Therapeutics Limited announced a change in the director’s interest, with Ellen Gwen Feigal acquiring 1,213,787 unlisted options exercisable at $0.10, expiring on 17 November 2029. This issuance of options was approved by shareholders at the company’s Annual General Meeting, reflecting a strategic move to align the interests of the director with the company’s long-term goals, potentially impacting its governance and stakeholder confidence.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is engaged in advancing targeted and cellular therapies to treat various forms of cancer, aiming to improve patient outcomes through precision medicine.
Average Trading Volume: 934,319
Technical Sentiment Signal: Hold
Current Market Cap: A$60.99M
See more data about PTX stock on TipRanks’ Stock Analysis page.